| Medical and Health Sciences | 2021-2025 | 77 | IE 1 | 99.98 |
| Epidemiology | Lifetime | 249 | IE 1 | 99.69 |
| Critical Care and Intensive Care Medicine | Lifetime | 25 | IE 1 | 99.53 |
| Infectious Diseases | Lifetime | 610 | IE 7 | 97.48 |
| Applied Microbiology and Biotechnology | Lifetime | 72 | IE 1 | 95.77 |
| Molecular Medicine | Lifetime | 532 | IE 3 | 79.05 |
| Critical Care and Intensive Care Medicine | 2021-2025 | 1 | IE 1 | 99.94 |
| Epidemiology | 2021-2025 | 25 | IE 1 | 99.89 |
| Infectious Diseases | 2021-2025 | 45 | IE 1 | 99.43 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 202 | IE 1 | 98.49 |
| Applied Microbiology and Biotechnology | 2021-2025 | 20 | IE 1 | 95.69 |
| Pneumonia and Respiratory Infections | Lifetime | 46 | IE 1 | 99.72 |
| COVID-19 Clinical Research Studies | Lifetime | 94 | IE 1 | 99.38 |
| Nosocomial Infections in ICU | Lifetime | 19 | IE 1 | 99.74 |
| Sepsis Diagnosis and Treatment | Lifetime | 61 | IE 1 | 99.65 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 73 | IE 1 | 99.36 |
| Long-Term Effects of COVID-19 | Lifetime | 101 | IE 1 | 98.82 |
| Antibiotic Use and Resistance | Lifetime | 66 | IE 1 | 99.43 |
| Respiratory Support and Mechanisms | Lifetime | 185 | IE 1 | 99.40 |
| Respiratory viral infections research | Lifetime | 486 | IE 1 | 98.24 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 418 | IE 1 | 98.01 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 331 | IE 1 | 98.17 |
| Emergency and Acute Care Studies | Lifetime | 408 | IE 3 | 97.80 |
| Influenza Virus Research Studies | Lifetime | 452 | IE 2 | 97.98 |
| Antifungal resistance and susceptibility | Lifetime | 446 | IE 5 | 97.62 |
| Hemodynamic Monitoring and Therapy | Lifetime | 667 | IE 5 | 96.55 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 1 | IE 1 | 99.88 |
| Pneumonia and Respiratory Infections | 2021-2025 | 1 | IE 1 | 99.91 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 4 | IE 1 | 99.70 |
| Nosocomial Infections in ICU | 2021-2025 | 1 | IE 1 | 99.95 |
| COVID-19 Clinical Research Studies | 2021-2025 | 31 | IE 1 | 99.72 |
| Respiratory Support and Mechanisms | 2021-2025 | 14 | IE 1 | 99.74 |
| Long-Term Effects of COVID-19 | 2021-2025 | 59 | IE 1 | 99.07 |
| Antibiotic Use and Resistance | 2021-2025 | 20 | IE 1 | 99.07 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 52 | IE 1 | 97.47 |
| Emergency and Acute Care Studies | 2021-2025 | 80 | IE 1 | 97.04 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 52 | IE 1 | 96.41 |
| Antifungal resistance and susceptibility | 2021-2025 | 79 | IE 1 | 98.06 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 82 | IE 1 | 96.82 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 166 | IE 1 | 94.25 |
| COVID-19 and healthcare impacts | 2021-2025 | 855 | IE 4 | 89.77 |
| Respiratory viral infections research | 2021-2025 | 724 | IE 1 | 90.31 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 950 | IE 3 | 91.18 |
| Thermal Regulation in Medicine | 2021-2025 | 158 | IE 1 | 82.67 |
| Inhalation and Respiratory Drug Delivery | 2021-2025 | 375 | IE 7 | 86.33 |
| Fungal Infections and Studies | 2021-2025 | 529 | IE 2 | 87.82 |
| Neutropenia and Cancer Infections | 2021-2025 | 612 | IE 1 | 74.39 |
| Bacterial Infections and Vaccines | 2021-2025 | 819 | IE 4 | 72.34 |
| Trauma, Hemostasis, Coagulopathy, Resuscitation | 2021-2025 | 693 | IE 3 | 72.64 |
